You are here

Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Floro, , 6900 Norway
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tobacco Use Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female daily smokeless tobacco users aged 18 years and older, who are
motivated to stop use of all tobacco products.

- Subjects must be daily users of nicotine containing smokeless tobacco and using
smokeless tobacco on at least 8 occasions per day averaged over a week.

- Have used smokeless tobacco for at least 1 year prior to screening with no period of
abstinence >3 months in the past year.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects using nicotine containing products (including smoking tobacco) other than
smokeless tobacco for 3 months prior to screening.

- Subjects with exhaled Carbon Monoxide (CO) >10 ppm at baseline.

- Subjects who have used varenicline, bupropion, or NRT within 3 months of screening.

- Subjects currently or within the past 12 months requiring treatment for depression or
have a current or prior history of panic disorder, psychosis, bipolar disorder or any
other serious mental illness.

NCT00717093
Pfizer
Completed
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03460977
All Genders
18+
Years
Multiple Sites
Smoking Cessation
NCT00143299
All Genders
18+
Years
Multiple Sites
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
A Randomized, Multicenter, Double Blind, Placebo Controlled Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
The primary goal of this study is to compare efficacy of varenicline to placebo for cessation of use of smokeless tobacco.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Tobacco Use Cessation
  • Drug: Varenicline Tartrate
    Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
    Other Name: Champix, Chantix, CP-526,555
  • Drug: Placebo
    Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
  • Experimental: Active
    Intervention: Drug: Varenicline Tartrate
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Fagerström K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010 Dec 6;341:c6549. doi: 10.1136/bmj.c6549.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
432
July 2009
April 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female daily smokeless tobacco users aged 18 years and older, who are motivated to stop use of all tobacco products.
  • Subjects must be daily users of nicotine containing smokeless tobacco and using smokeless tobacco on at least 8 occasions per day averaged over a week.
  • Have used smokeless tobacco for at least 1 year prior to screening with no period of abstinence >3 months in the past year.

Exclusion Criteria:

  • Subjects using nicotine containing products (including smoking tobacco) other than smokeless tobacco for 3 months prior to screening.
  • Subjects with exhaled Carbon Monoxide (CO) >10 ppm at baseline.
  • Subjects who have used varenicline, bupropion, or NRT within 3 months of screening.
  • Subjects currently or within the past 12 months requiring treatment for depression or have a current or prior history of panic disorder, psychosis, bipolar disorder or any other serious mental illness.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Norway,   Sweden
 
 
NCT00717093
A3051104
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now